PTO/SB/088 (09-05

Approved for use through 03/31/207. OMB 0651-0031
U.S. Patent and Tradement Office; U.S. DEPARTMENT OF COMMERCE

Emily B. Bernhardt

453-IIS-PCT

Use Person and 1 Indication And of 1985, as paragraph and needed in Annual 1 Indication Crisis as 1 (1994)

Examiner Name

Sheet 2

of 2

Attorney Docket Num

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HALEBLIAN, JOHN, et al., "Pharmaceutical Applications of Polymorphism", Journal of Pharmaceutical Sciences, August 1969, pp. 911-929, Vol. 58, No. 8.	
		DAVIES, Huw M. L., et al., "Asymmetric Synthesis of (+)-Indetraline Using Rhodlum-Catalyzed C-H Activation", Tetrahedron Letters, 2002, pp. 4951-4953, 43, Pergamon.	
		_	
			Г
	i		

Examiner		Date	

Signature | Lossands ou |

"EXAMINER: Inflat of reference considered, whether or not classion as in conformance with MPEP 609. Draw line through chalcon if not in conformance and not considered, include copy of this form with next communication to expected.

considered, found copy of this form with real communication the appears.

Appeared in the absolute designation makes included. Papeared in a space a closed, mark here il Eligide to require il residential or a space and in the communication of the process of the communication of the